23-MULTI-63-FFP (FF10832-PEM-201): A Phase 2a Study with Safety Run-in to Evaluate the Safety, Tolerability, and Preliminary Efficacy of FF-10832 Monotherapy or in Combination with Pembrolizumab in Patients with Advanced

Grants and Contracts Details

StatusActive
Effective start/end date2/15/24 → 2/15/26

Funding

  • Fujifilm Pharmaceuticals USA Incorporated: $2.00